Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00518765 · ClinicalTrials.gov registry record · Phase 3
Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
NCT00518765 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 32 participants.
The verdict
NCT00518765, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will measure the effects of different doses of aliskiren on kidney blood flow and function in healthy adults and determine how salt intake affects the response to aliskiren.
Interventions
- DRUG Aliskiren
- DRUG Aliskiren plus placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2005-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00518765
The ClinicalTrials.gov registry entry for NCT00518765 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aliskiren is the first listed.
NCT00518765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00518765 about?
NCT00518765 is a clinical study titled "Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet". This study will measure the effects of different doses of aliskiren on kidney blood flow and function in healthy adults and determine how salt intake affects the response to aliskiren.
What is the current status of trial NCT00518765?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2005-10.
What interventions are being tested in trial NCT00518765?
The interventions under investigation include: Aliskiren (DRUG), Aliskiren plus placebo (DRUG).
Who is sponsoring clinical trial NCT00518765?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.